APA (7th ed.) Citation

M, B., A, M., F, A., N, V., F, F., J, S., . . . NS, P. (2025). The Novel SSTR3 Full Agonist ITF2984 Shows Antitumor Properties against Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 115(5), 446. https://doi.org/10.1159/000543136

Chicago Style (17th ed.) Citation

M, Bistika, Marangelo A, Ascione F, Valentini N, Fedeli F, Schrader J, Modena D, Steinkühler C, and Pellegata NS. "The Novel SSTR3 Full Agonist ITF2984 Shows Antitumor Properties Against Pancreatic Neuroendocrine Tumors." Neuroendocrinology 115, no. 5 (2025): 446. https://doi.org/10.1159/000543136.

MLA (9th ed.) Citation

M, Bistika, et al. "The Novel SSTR3 Full Agonist ITF2984 Shows Antitumor Properties Against Pancreatic Neuroendocrine Tumors." Neuroendocrinology, vol. 115, no. 5, 2025, p. 446, https://doi.org/10.1159/000543136.